Keyphrases
Antineoplastic Drugs
32%
BRAF Inhibitor (BRAFi)
42%
Breast Cancer Radiation Therapy
28%
Cancer Patients
28%
Cardiotoxicity
28%
Clinical Benefit
22%
Confidence Interval
28%
Cough
18%
Denmark
24%
Disease Progression
33%
Dyspnea
35%
Electronic Patient-reported Outcome (ePRO)
32%
Hazard Ratio
20%
Health-related Quality of Life
20%
Immune Checkpoint Inhibitors
21%
In Cancer
28%
Incidence Risk
28%
Intracranial Metastases
18%
Ipilimumab
35%
Leptomeningeal Disease
28%
Locally Advanced Breast Cancer
28%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
56%
Lung Radiation
28%
Malignant Disease
28%
Mean Lung Dose
28%
Median Overall Survival
27%
Melanoma
28%
Melanoma Brain Metastases
56%
Metastatic Melanoma
44%
Mini
28%
Modern History
28%
Nivolumab
35%
Overall Response Rate
23%
Overall Survival
52%
Patient-clinician Communication
28%
Patient-reported Outcomes
84%
Patient-Reported Outcomes Measurement Information System (PROMIS)
60%
Prognostic Risk Factors
28%
Progression-free Survival
18%
Radiation Dose
28%
Real-life Cohort
28%
Remote Symptom Monitoring
28%
Respiratory Symptoms
28%
Risk Assessment System
28%
Risk Factors
28%
Routine Care
28%
Single Institution
33%
Solitary Fibrous Tumor
28%
Survival Improvement
28%
Unrecognized Myocardial Infarction
28%
Medicine and Dentistry
Arm
28%
Asthma
5%
Brain Metastasis
28%
Breast Cancer
28%
Cancer Radiotherapy
28%
Carboplatin
5%
Cardiotoxicity
28%
Chronic Kidney Disease
5%
Clinical Decision Making
5%
Clinician
62%
Coughing
15%
Disease Exacerbation
33%
Dyspnea
27%
Electronic Health Record
5%
Endometriosis
5%
Hazard Ratio
21%
Heart Left Ventricle Ejection Fraction
15%
Hemoptysis
5%
ICD-10
5%
Immune Checkpoint Inhibitor
14%
Lung
28%
Lung Cancer
62%
MEK Inhibitor
37%
Melanoma
28%
Metastatic Melanoma
33%
Non Small Cell Lung Cancer
5%
Outcome Assessment
28%
Overall Survival
61%
Patient Distribution
5%
Patient Monitoring
28%
Patient-Reported Outcome
100%
Primary Outcome
5%
Quality of Life Analysis
5%
Randomized Controlled Trial
28%
Recurrent Disease
16%
Retrospective Study
28%
Small Cell Lung Cancer
5%
Solitary Fibrous Tumor
28%
Subgroup Analysis
5%
Vinorelbine
5%